Kohl’s Shows CEO the Door
Kohl’s (NYSE:KSS) removed Ashley Buchanan as CEO following an investigation that uncovered company policy violations, the department store chain said on Thursday.The move comes after Buchanan was appointed to the top job in November, replacing Tom Kingsbury.A board investigation found Buchanan directed the company to engage in vendor transactions that involved undisclosed conflicts of interest, Kohl’s said, adding that Buchanan’s removal did not affect its financial reporting or other employees.The department store chain named Michael Bender as its interim CEO, effective immediately, and said it would begin a search for a permanent chief executive.Kohl’s also provided preliminary first-quarter results, with the company expected to report earnings on May 29.The company has been grappling with weak demand for several quarters as department stores struggle to attract consumers due to stiff competition from e-commerce firms and big-box retailers such as Walmart (NYSE:WMT) and Costco (NASDAQ:CSCO) Kohl’s expects first-quarter comparable sales to fall between 4.3% and 4%, compared with analysts’ average expectation of a 6.34% decrease, according to data compiled by LSEG.The company expects a loss per share in the range of 24 cents to 20 cents, compared with estimates of a loss of 52 cents.KSS shares picked up 39 cents, or 5.9%, to $5.10
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


